EDSA Stock Analysis: Buy, Sell, or Hold?
EDSA - Edesa Biotech, Inc. Common Shares
$1.23
0.06 (5.13%)
▲
5d:
-14.58%
30d:
-13.38%
90d:
-34.22%
WAIT
LOW Confidence
Last Updated: February 2, 2026
Earnings: Feb 13, 2026
9d
Get Alerted When EDSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called EDSA this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EDSA is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EDSA is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EDSA is currently trading at $1.23, which is considered oversold relative to its 30-day fair value range of $1.34 to $1.52.
Technical Outlook: Technically, EDSA is in a strong downtrend. Immediate support is located at $1.07, while resistance sits at $1.54. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: EDSA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.00 (+794.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EDSA is in a strong downtrend. Immediate support is located at $1.07, while resistance sits at $1.54. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: EDSA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.00 (+794.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.34 -
$1.52
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 794.3% below Wall St target ($11.00)
- WARNING: Recommendation downgraded due to -14.6% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.34 -
$1.52
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.07
Resistance Level
$1.54
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.67
Wall Street Target
$11.00
(+794.3%)
Revenue Growth (YoY)
-99.9%
Last updated: February 02, 2026 11:40 PM ET
Data refreshes hourly during market hours. Next update: 12:40 AM
Data refreshes hourly during market hours. Next update: 12:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 61 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 52 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 53 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
